Scholar Rock Holding Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 19, 2018, details a strategic partnership between Scholar Rock Holding Corporation (the "Company") and Gilead Sciences, Inc. ("Gilead"). The filing reports the entry into a Master Collaboration Agreement and a concurrent equity investment transaction.
Key Financial Metrics and Transaction Terms
The filing outlines significant capital inflows and potential future revenue streams associated with the collaboration:
- Upfront Cash Payment: Gilead will pay Scholar Rock $50 million upon the agreement's effective date.
- Equity Investment: Gilead purchased 980,392 shares of Scholar Rock common stock for approximately $30 million at $30.60 per share.
- Ownership Stake: Following the transaction, Gilead beneficially owns approximately 3.7% of the Company's outstanding common stock.
- Development Milestone: A one-time payment of $25 million is payable upon successful demonstration of in vivo proof of concept.
- Total Potential Consideration: The aggregate potential payments (including option exercise fees, development, regulatory, and commercial milestones) total $475 million per Program.
- Royalties: Gilead will pay tiered royalties ranging from high single-digits to low double-digits on net sales of licensed products.
Material Changes and Strategic Direction
The primary material change is the establishment of an exclusive research and pre-clinical development collaboration focused on three separate programs outside the field of oncology. Scholar Rock will conduct research to identify "Program Antibodies," while Gilead retains an exclusive option to license these programs for development and commercialization. A Joint Steering Committee (JSC) will oversee strategic direction and candidate selection.
Outlook, Risks, and Contingencies
Outlook and Management Commentary: The collaboration aims to characterize and identify program antibodies meeting specific development criteria. If Scholar Rock fails to demonstrate in vivo proof of concept within a specified period, the parties will discuss reallocating resources or introducing new research programs.
Risks and Contingencies:
- Termination Rights: Gilead may terminate the agreement in its sole discretion with prior written notice. Termination also occurs immediately if Gilead rejects a development candidate nomination for the second time.
- Option Exercise: Gilead's option to license a program is discretionary and must be exercised within a specific window following the Research Collaboration Term.
- Regulatory and Development Risk: Future payments are contingent upon achieving specific research, regulatory, and commercial milestones, which are not guaranteed.
Investor Verification Checklist
- Verify the exact terms of the "in vivo proof of concept" criteria required to trigger the $25 million milestone payment.
- Confirm the specific definition of the "Field" to ensure no overlap with Scholar Rock's existing oncology pipeline.
- Review the full text of the Share Purchase Agreement for specific lock-up restrictions and standstill provisions regarding Gilead's 3.7% stake.
- Monitor the status of the Irrevocable Registration Rights Waiver and Amendment required from existing investors.
- Assess the timeline for the Research Collaboration Term (up to three years or until a development candidate is approved) to gauge cash flow timing.